Lupin expands operations in Japan, receives 10 product approvals

New Delhi, Apr 23 (UNI) Pune-based anti-tuberculosis drug major Lupin Ltd, today said its subsidiary in Japan, Kyowa Pharmaceutical Industry Co Ltd, (Kyowa) has received approvals for 10 products from the Japanese Government.

The company expects to launch these products in July 2008 post NHI listing. The approval has been given by the Ministry of Health and Labour Welfare (MHLW), Japan.

Kyowa's expanded product basket will now include ten more products and these are Amlodipine (CVS), Risperidone (line extension: CNS), Cabergoline (CNS), Milnacipran (CNS), Tandospirone (CNS), Meloxicam (NSAID), Fluticasone (line extension for pediatrics: Anti-Asthma), Quazepam (line extension CNS), Ethyl Icosapentate (line extension) and Maprotiline (line extension CNS).

The combined market size of these molecules in Japan is JPY 265 Bn (2.65 billion dollars) as per IMS 2007.

Lupin had acquired Kyowa in October 2007 and it is currently focusing on enriching its product basket and expanding its therapy width. These fresh approvals will strengthen Lupin's position in the worlds' second largest pharmaceutical market.

UNI BJR AK PM1708